Treatment of childhood acute myeloid leukemia

Expert Review of Anticancer Therapy

Volumn 5, Issue 5, 2005, Pages 917-929

  ter Bals, Edske ^a   Kaspers, Gertjan J L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Children; Minimal residual disease; Novel agents; Pharmacogenomics; Therapy; Tyrosine kinase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICONVULSIVE AGENT; CD33 ANTIGEN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; DAUNORUBICIN; DEHYDRODIDEMNIN B; DNA; ETOPOSIDE; FLT3 LIGAND; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; IMATINIB; MERCAPTOPURINE; METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; MITOXANTRONE; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; R 11577; RETINOIC ACID; STEM CELL FACTOR; THALIDOMIDE; TIOGUANINE; TIPIFARNIB; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; CYTOGENETICS; DIAGNOSTIC PROCEDURE; DOWN SYNDROME; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; GENE TARGETING; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HUMAN; HYPOTHYROIDISM; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; NEUROLOGIC DISEASE; OBESITY; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SEIZURE; SHORT STATURE; SIDE EFFECT;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CLINICAL TRIALS; CRANIAL IRRADIATION; DOWN SYNDROME; HUMANS; LEUKEMIA, MYELOID; NEOPLASM, RESIDUAL; PROGNOSIS; QUALITY OF LIFE; REMISSION INDUCTION; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 27744598066     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.5.917     Document Type: Review

References (90)

1. Zwaan ChM, Kaspers GJL. Possibilities for tailored and targeted therapy in paediatric acute myeloid leukemia. Br. J. Haematol. 127, 264-279 (2004).
2. Kaspers GJL, Ravindranath Y. Acute myeloid leukemia in children and adolescents. In: Textbook of Malignant Haematology. Degos L, Griffin JD, Linch DC, Löwenberg B (Eds). Martin Dunitz, London, UK, 617-632 (2005).
3. Weinstein HJ. Acute Myeloid Leukemia. In: Childhood Leukemias. Pui Ch-H (Ed.). Cambridge University Press, Cambridge, UK, 322-331 (2000).
4. Pui Ch-H. Childhood leukemias. N. Engl. J. Med. 332, 1618-1630 (1995).
5. Greaves M. Pre-natal origins of childhood leukemia. Rev. Clin. Exp. Hematol. 7, 233-245 (2003).
6. Wiemels JL, Xiao Z, Buffler PA et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 99, 3801-3805 (2002).
7. Tenen DG, Hromas R, Licht JD, Zhang D-E. Transciption factors, normal myeloid development, and leukemia. Blood 90, 489-519 (1997).
8. Löwenberg B, Downing JR. Burnett A. Acute myeloid leukemia. N. Engl. J. Med. 341, 1051-1062 (1999).
9. Deguchi K, Gilliland DG. Co-operativety between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia 16, 740-744 (2002).
10. Goemans BF, Zwaan ChM, Miller M et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19, 1536-1542 (2005).
11. Ribeiro RC, Razzouk BI, Pui Ch-H, Rubnitz JE. Acute myeloid leukemia in children and adolescents. Hematology 129-145 (2004).
12. Bennett JM, Catovsky D, Daniel MT et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Co-operative Group. Ann. Intern. Med. 103, 460-462 (1985).
13. Bennett JM, Catovsky D, Daniel MT et al. Proposal for the regognition of minimally differentiated acute myeloid leukemia (AML-0). Br. J. Haematol. 78, 325-329 (1991).
14. Pui C-H, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 78, 1449-1463 (1990).
15. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J. Clin. Oncol. 17, 3835-3849 (1999).
16. Vardiman JW, Harris NL, Brunning RD. The World Health Organisation (WHO) classification of the acute myeloid neoplasms. Blood 100, 2292-2302 (2002).
17. Creutzig U, Kaspers GJL. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. 22, 3432-3433 (2004).
18. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J. Clin. Oncol. 22, 4384-4393 (2004).
19. Bloomfield CD. Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. Leukemia 6(Suppl. 4), 65-67 (1992).
20. Bloomfield CD, Lawrence D, Byrd JC et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 58, 4173-4179 (1998).
21. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92, 2322-2333 (1998).
22. Creutzig U, Zimmermann M, Ritter J et al. Definition of a standard-risk group in children with AML. Br. J. Haematol. 104, 630-639 (1999).
23. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 75, 1932-1940 (1990).
24. Ravindrinath Y, Abella E, Krischer JP et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncolgy Group AML Study 8498. Blood 80, 2210-2214 (1992).
25. Creutzig U, Ritter J, Ludwig WD et al. Acute myeloid leukemia in children with Down's syndrome. Klin. Padiatr 207, 136-144 (1995).
26. Lange BJ, Kobrinsky N, Barnard DR et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 91, 608-615 (1998).
27. Lie SO, Jonmundsson G, Mellander L et al. A population-based study of 272 children with acute myeloid leukemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paeditric Haematology and Oncology (NOPHO). Br. J. Haematol. 94, 429-436 (1996).
28. Lie SO, Abrahamsson J, Clausen N et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br. J. Haematol. 122, 217-225 (2003).
29. Ravindrinath Y. Down's syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. J. Clin. Oncol. 21, 3385-3387 (2003).
30. Rubnitz JE, Raimondi SC, Tong X et al. Favorable impact of t(9; 11) in childhood acute myeloid leukemia. J. Clin. Oncol. 20, 2302-2309 (2002).
31. Kawasaki H, Isoyama K, Eguchi M et al. Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. Blood 98, 3589-3594 (2001).
32. Wheatley K, Burnett AK, Goldstone AH et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br. J. Haematol. 107, 69-79 (1999).
33. Abu-Duhier FM, Goodeve AC, Wilson GA et al. FTL3 internal tandem duplication mutations in adult acute myeloid leukemia define a high-risk group. Br. J. Haematol. 111, 190-195 (2000).
34. Kottaridis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98, 1752-1759 (2001).
35. Meshinchi S, Woods WG, Stirewalt DL et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97, 89-94 (2001).
36. Kiyoi H, Naoe T, Nakano Y et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93, 3074-3080 (1999).
37. Zwaan ChM, Meshinchi S. Radich JP et al Flt3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 102, 2387-2394 (2003).
38. Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, Sauerbrey A. Response to chemotherapy and expression of the genes encoding the Multi-drug resistance-associated Proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin. Cancer Res. 9, 1083-1086 (2003).
39. Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, Sauerbrey A. BRCP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16, 1443-1447 (2002).
40. List AF, Kopeckey KJ, Willman CL et al. Benefit of cyclosporin modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98, 3212-3220 (2001).
41. Kaspers GJL, Veerman AJP. Clinical significance of cellular drug resistance in childhood leukemia. Recent Results Cancer Res. 161, 196-220 (2003).
42. Zwaan CM, Kaspers GJL, Pieters R et al. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 100, 3352-3360 (2002).
43. Zwaan CM, Kaspers GJL, Pieters R et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 96, 2879-2886 (2000).
44. Evans WE, Crom WR, Abromowitch M et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia: identification of a relation between concentration and effect. N. Engl. J. Med. 314, 471-477 (1986).
45. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 338, 499-505 (1998).
46. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvement in outcome with chemotherapy alone in pediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukemia Working Party. Br. J. Haematol. 101, 130-140 (1998).
47. Campana D, Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta. Haematol. 112, 8-15 (2004).
48. Sievers EL, Lang BJ, Alonzo TA et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from retrospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 101, 3398-3406 (2003).
49. Lacayo NJ, Meshinchi S, Kinnunen P et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 104, 2646-2654 (2004).
50. Liang DC, Shih LY, Huang C-F et al. CEBPα. mutations in childhood acute myeloid leukemia. Leukemia 19, 410-414 (2005).
51. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NCS-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 57, 485-488 (1973).
52. Yates JW, Glidewell O, Wiernik P et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60, 454-462 (1982).
53. Weinstein HJ, Mayer RJ, Rosenthal DS et al. Treatment of acute myelogenous leukemia in children and adults. N. Engl. J. Med. 303, 473-478 (1980).
54. Hann IM, Stevens RF, Goldstone AH et al. Randomized comparison of DAT versus ADE as introduction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Reasearch Council's 10th AML trial (MRC AML 10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 89, 2311-2318 (1997).
55. Perel Y, Auvrignon A, Leblanc T et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. J. Clin. Oncol. 20, 2774-2782 (2002).
56. O'Brien TA, Russell SJ, Vowels MR et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zeeland Childen's Cancer Study Group. Blood 100, 2708-2716 (2002).
57. Creutzig U, Ritter J, Zimmermann M et al. Improved treatment results in high- risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J. Clin. Oncol. 19, 2705-2713 (2001).
58. Ravindranath Y, Yeager AM, Chang MN et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood, Pediatric Oncology Group. N. Engl. J. Med. 334, 1428-1434 (1996).
59. Woods WG, Kobrinsky N, Buckley JD et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 87, 4979-4989 (1996).
60. Ravindranath Y, Steuber CP, Krischer J et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J. Clin. Oncol. 9, 572-580 (1991).
61. Steuber CP, Culbert SJ, Ravindranath Y et al. Therapy of childhood acute nonlymphocytic leukemia: the Pediatric Oncology Group experience (1977-1988). Hamatol. Bluttransfus. 33, 198-209 (1990).
62. Creutzig U, Ritter J, Riehm H, Budde M, Schellong G. The childhood AML studies BFM-76 and -83: treatment results and risk factor analysis. Hamatol. Bluttransfus. 30, 71-75 (1987).
63. Kell WJ, Burnett AK, Chopra R et al. A feasability study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102, 4277-4283 (2003).
64. Zwaan ChM, Reinhardt D, Corbacioglu S et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate use basis. Blood 101, 3868-3871 (2003).
65. Capizzi RL, Powell BL. Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias. Semin. Oncol. 14(2 Suppl. 1), 40-50 (1987).
66. Capizzi RL, Davis R, Powell B et al. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia - a Cancer and Leukemia Group B study. J. Clin. Oncol. 6, 499-508 (1988).
67. Wells RJ, Odom LF, Gold SH et al. Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multi-drug resistance gene 1. Med Pediatr Oncol. 22, 244-249 (1994).
68. Dahl GV, Lacayo NJ, Brophy N et al. Mitoxantrone, etoposide, and cyclosporin therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J. Clin. Oncol. 18, 1867-1875 (2000).
69. Michel G, Baruchel A, Tabone MD et al. Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Hematol. Cell. Ther. 38, 169-176 (1996).
70. Godder K, Eapen M, Layer JH et al. Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second remission: prognostic factor analysis. J. Clin. Oncol. 22, 3798-3804 (2004).
71. Burnett AK, Goldstone AH, Stevens R et al. Allo and auto BMT reduce relapse risk in AML in CR1 but do not significantly improve overall survival: results of the MRC AML 10 Trial. Br. J. Haematol. 93(Suppl. 2), 313 (1996).
72. Cassileth PA, Harrington DP, Appelbaum FR et al. Chemotherapy compared with autologeous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N. Engl. J. Med. 339, 1649-1656 (1998).
73. Keating S, de Witte T, Suciu S et al. The influence of HLA-sibling donor availability on treatment outcome of patients with AML: an analysis of the AML 8A study of the EORTC Leukemia Co-operative Group and GIMEMA. Br. J. Haematol. 102, 1344-1353 (1998).
74. Woods WG, Neudorf S, Sanders J et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group. Blood 97, 56-62 (2001).
75. Abbott BL, Rubnitz JE, Tong X et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. Leukemia 17, 2090-2096 (2003).
76. Webb DKH, Wheatley K, Harrison G et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. Leukemia 13, 25-31 (1999).
77. Leung W, Hudson MM, Strickland DK et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J. Clin. Oncol. 18, 3273-3279 (2000).
78. Kojima S, Sako M, Kato K et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia 14, 786-791 (2000).
79. Gamis AS, Woods WG, Alonzo TA et al. Increased age at diagnosis has significantly negative effect on outcome in children with Down's syndrome and acute myeloid leukemia: a report from Children's Cancer Group Study 2891. J. Clin. Oncol. 21, 3415-3422 (2003).
80. Zwaan ChM, Kaspers GJL, Pieters R et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down's syndrome. Blood 99, 245-251 (2002).
81. Mann G, Reinhardt D, Ritter J et al. Treatment with all-trans retinoic acid in acute promyelocytic lekemia reduces early deaths in children. Ann. Hematol. 80, 417-422 (2001).
82. Bapna A, Nair R, Tapan KS et al. All-transretinoic acid (ATRA): pediatric acute promyelocytic leukemia. Oncology 15, 243-248 (1998).
83. Fenaux P. Chastang C, Chevret S et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia, The European APL Group. Blood 94, 1192-1200 (1999).
84. Testi AM, Biondi A, Lo Coco F et al. GIMEMA-AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia in children. Blood 106, 447-453 (2005).
85. Kaspers GJL. Targeted monoclonal antibody-based treatment of hematological malignancies (Editorial). Expert Rev. Anticancer Ther. 3, 253-255 (2003).
86. Kindler T, Breitenbuecher F, Marx A et al. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood 101, 2960-2962 (2003).
87. Smith BD, Levis M, Beran M et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukaemia. Blood 103, 3669-3676 (2004).
88. Stone RM, DeAngelo DJ, Klimek V et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105, 54-60 (2005).
89. Goemans BF, Zwaan CM, Harlow A et al. In vitro profiling of the sensitivity of pediatric leukaemia cells to tipifarnib (Zarnestra): identification of T-cell ALL and FAB type M5 AML as the most sensitive subsets. Blood (2005) (In Press).
90. Bresters D, Broekhuizen AJF, Kaaijk P. Faircloth GT, Jimeno J, Kaspers GJL. In vitro cytotoxicity of Aplidine and cross-resistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples; a rational basis for clinical development. Leukemia 17, 1338-1343 (2003).